MRP ₹85
(Inclusive of all Taxes)
₹11.5 Cashback (14%)
Extra 15% Off with Bank Offers
coupon
Prescription drugWhats That
संघटन :
क्लिंडामाइसिन-1%W/W
निर्माता/विपणक :
इंटास फार्मास्यूटिकल्स लिमिटेड
उपभोग प्रकार :
सामयिक
वापसी नीति :
वापसी योग्य नहीं
को या उसके बाद समाप्त हो जाएगा :
अप्रैल-24
Secure Payment
Trusted by 8 Crore Indians
Genuine Products
Author Details
Disclaimer
While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.
शराब
Caution
कोई भी परस्पर क्रिया नहीं पाई गई/स्थापित नहीं हुई। यदि आपको कोई चिंता है तो कृपया अपने डॉक्टर से परामर्श करें।
गर्भावस्था
Caution
यदि आप गर्भवती हैं या गर्भधारण की योजना बना रही हैं तो कृपया Acwak 1% Gel का उपयोग करने से पहले अपने चिकित्सक से परामर्श करें।
स्तनपान
Caution
यदि आप स्तनपान करा रही हैं तो कृपया Acwak 1% Gel का उपयोग करने से पहले अपने डॉक्टर से परामर्श करें। यदि आपको अपने स्तनों पर क्रीम, जेल या लोशन लगाने की आवश्यकता है, तो स्तनपान कराने से कुछ समय पहले ऐसा न करें।
ड्राइविंग
Safe if prescribed
Acwak 1% Gel का वाहन चलाने या मशीनों का उपयोग करने की क्षमता पर कोई या नगण्य प्रभाव नहीं पड़ता है।
जिगर
Caution
यदि आपको यकृत रोग का कोई इतिहास है तो Acwak 1% Gel का उपयोग करने से पहले अपने डॉक्टर को बताएं।
किडनी
Caution
यदि आपको किडनी रोग का कोई इतिहास है तो Acwak 1% Gel का उपयोग करने से पहले अपने डॉक्टर को बताएं।
बच्चे
Unsafe
Acwak 1% Gel की अनुशंसा 12 वर्ष से कम आयु के बच्चों के लिए नहीं की जाती है।
Product Substitutes
Drug-Drug Interactions
No Drug - Drug interactions found in our data. We may lack specific data on this medicine and are actively working to update our database. Consult your doctor for personalized advice
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
CLINDAMYCIN-1%W/WOther bacterial intestinal infections
Severe
CLINDAMYCIN-1%W/WDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
Drug-Diseases Interactions
Login/Sign Up
CLINDAMYCIN-1%W/WOther bacterial intestinal infections
Severe
How does the disease interact with Acwak 1% Gel:
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
CLINDAMYCIN-1%W/WDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
How does the disease interact with Acwak 1% Gel:
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
CLINDAMYCIN-1%W/WOther diseases of liver
Moderate
How does the disease interact with Acwak 1% Gel:
The liver is the primary site of Acwak 1% Gel metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Acwak 1% Gel and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Acwak 1% Gel therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Acwak 1% Gel is primarily metabolized by the liver. Therapy with Acwak 1% Gel should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
The liver is the primary site of Acwak 1% Gel metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Acwak 1% Gel and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Acwak 1% Gel therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Acwak 1% Gel is primarily metabolized by the liver. Therapy with Acwak 1% Gel should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/WOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Acwak 1% Gel:
Acwak 1% Gel is partially removed by the kidney. Acwak 1% Gel should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Acwak 1% Gel concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Acwak 1% Gel should be administered cautiously in patients with severely impaired renal function. Serum Acwak 1% Gel concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Acwak 1% Gel is partially removed by the kidney. Acwak 1% Gel should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Acwak 1% Gel concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Acwak 1% Gel should be administered cautiously in patients with severely impaired renal function. Serum Acwak 1% Gel concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/WOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Acwak 1% Gel:
Acwak 1% Gel is partially removed by the kidney. Acwak 1% Gel should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Acwak 1% Gel concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Acwak 1% Gel should be administered cautiously in patients with severely impaired renal function. Serum Acwak 1% Gel concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Acwak 1% Gel is partially removed by the kidney. Acwak 1% Gel should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Acwak 1% Gel concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Acwak 1% Gel should be administered cautiously in patients with severely impaired renal function. Serum Acwak 1% Gel concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Have a query?